Aclaris Therapeutics, Inc. Debt Securities, Available-for-sale, Noncurrent
Aclaris Therapeutics, Inc. (ACRS) had Debt Securities, Available-for-sale, Noncurrent of $79.06 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Noncurrent $79.06M.
- 2026-03-31: Debt Securities, Available-for-sale, Noncurrent $85.37M.
- 2025-12-31: Debt Securities, Available-for-sale, Noncurrent $60.61M.
- 2025-09-30: Debt Securities, Available-for-sale, Noncurrent $71.30M.
| Period end | Debt Securities, Available-for-sale, Noncurrent |
|---|---|
| 2026-06-30 | $79.06M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $85.37M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $60.61M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $71.30M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $81.08M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $85.21M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $90.30M 10-K · filed 2026-02-26 |
| 2024-09-30 | $45.71M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $38.78M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $33.20M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $62.77M 10-K · filed 2025-02-27 |
| 2023-09-30 | $83.94M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $90.99M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $33.60M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $12.24M 10-K · filed 2024-02-27 |
| 2022-06-30 | $7.22M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $23.95M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $34.24M 10-K · filed 2023-02-23 |
| 2021-09-30 | $45.73M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $34.50M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $14.36M 10-Q · filed 2021-05-07 |
| 2017-12-31 | $15.00M 10-K · filed 2019-03-18 |
| 2017-03-31 | $8.02M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $36.91M 10-K · filed 2018-03-12 |
| 2015-12-31 | $7.17M 10-K · filed 2017-03-15 |
| 2014-12-31 | $518.00K 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |